klinische Pharmakologie

Prof. Dr. med. Bernd Rosenkranz

Kapstadt / Südafrika

klinische Pharmakologie

Prof Dr. med. Bernd Rosenkranz, FFPM

 Prof Bernd Rosenkranz holds a medical degree from the University of Düsseldorf, is board certified Clinical Pharmacologist in Germany and South Africa, and Fellow of the Faculty of Pharmaceutical Medicine (FFPM). In 1994, he qualified as university lecturer (habilitation) at the Medical Faculty of the Philipps University Marburg with the venia legendi for Clinical Pharmacology; in 2001 he received the venia legendi for Clinical Pharmacology from the Medical Faculty, Humboldt University Berlin (Charité).

He spent 23 years in industry, as Director of Clinical Pharmacology at Hoechst/Hoechst Marion Roussel in Germany, France and USA, Chief Medical Officer at 3ClinicalResearch in Berlin/Hennigsdorf, Germany, and Vice President Clinical Development at Jerini, Berlin, Germany, where he was responsible for the world-wide clinical programme of icatibant in hereditary angioedema. In 2008, he was appointed Professor and Head of the Division of Clinical Pharmacology (Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa) from which he retired in 2016. In 2010, he established a postgraduate programme in Pharmaceutical Medicine / Medicines Development which received recognition as Centre of Excellence in 2014 by the PharmaTrain Federation.

Bernd Rosenkranz is co-founder and President of the Fundisa African Academy of Medicines Development, board member of the South African Society for Basic and Clinical Pharmacology (SASBCP), and secretary of the College of Clinical Pharmacologists (Colleges of Medicine of South Africa), He is member of various international organisations, such as the International Committee of the UK Faculty of Pharmaceutical Medicine, the Membership Committee of the International Union of Basic and Clinical Pharmacology (IUPHAR), the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT), the Arbeitsgemeinschaft für Angewandte Humanpharmakologie (AGAH), the American Society for Clinical Pharmacology and Therapeutics (ASCPT), the PharmaTrain Federation, and the PharmaTrain Certification Board.  He is co-chair of the IFAPP-PharmaTrain “Medicines Development and Regulation: Working Group on Education in Low and Middle Income Countries”. He was chair of the Finance Committee of the 17th World Conference of Basic and Clinical Pharmacology (WCP2014) held in Cape Town.

His work is presented in 102 original publications, 17 book chapters, 64 invited lectures/chairmanships, and 126 conference presentations. He is Associate Editor of Frontiers in Pharmaceutical Medicine and Outcomes Research and of the Journal of Medicines Development Sciences.

Bernd Rosenkranz is board member of the Manenberg Aftercare Centre, Manenberg, Cape Town.

Prof. Dr. med. Harry Selker

Boston / USBoston/US

klinische Pharmakologie

Harry P. Selker, MD, MSPH is Dean of Tufts Clinical and Translational Science Institute (CTSI) (www.tuftsctsi.org) at Tufts University, and Executive Director of the Institute for Clinical Research and Health Policy Studies (www.icrhps.org) at Tufts Medical Center.  As Dean of Tufts CTSI, he provides leadership and is responsible for the programs and infrastructure that support clinical and translational research at the Tufts University Schools and affiliated hospitals, and other academic, community-based, and industry CTSI partners. He practices medicine at Tufts Medical Center.

Dr. Selker‘s research focuses on the development of treatment strategies, decision aids, and systems aimed at improving medical care.  He is known for a series of studies of the factors influencing emergency cardiac care and for development of „clinical predictive instruments,“ mathematical models that are used as decision aids.  They provide emergency physicians and paramedics with predictions for their patients’ likely cardiac diagnoses and outcomes for real-time use in clinical care.  This has included conduct of multiple large national clinical effectiveness trials that have demonstrated better treatment and clinical outcomes for patients with acute coronary syndromes. Additionally, Dr. Selker has done research to advance clinical study design, execution, issues around informed consent, data analysis, mathematical predictive modeling of medical outcomes, and comparative effectiveness research.

Dr. Selker also has contributed to health services and health policy research, with a focus on translational research that ultimately has impact on the public’s health.  He has advised policymakers around healthcare delivery and medical research, including the House and Senate authors of the Affordable Care Act.  Nationally, Dr. Selker has served as president of the Society of General Internal Medicine, of the Society for Clinical and Translational Science, and of the Association for Clinical Research Training, and serves on boards of organizations and Federal agencies.  He is currently President of the Association for Clinical and Translational Science and Chairman of the Clinical Research Forum.

ao Univ.-Prof. Dr. Michael Wolzt

Wien / AT

klinische Pharmakologie